Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 1, 2012, Pages 53-60

  Ito, Sunao ^a   Tajima, Koyuki ^a   Nogawa, Masaki ^a   Inoue, Naoki ^a   Kyoi, Takashi ^a   Takahashi, Yosuke ^a   Sasagawa, Takahiro ^a   Nakamura, Akio ^a   Kotera, Takashi ^a   Ueda, Makoto ^a   Yamashita, Yasuhiro ^a   Banno, Kouji ^b  

^a NIPPON SHINYAKU CO LTD   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; DULOXETINE; ETODOLAC; INDOMETACIN; MEXILETINE; PACLITAXEL; PREGABALIN;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENTIATION; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE FIBER DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; WITHDRAWAL REFLEX;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ETODOLAC; GAMMA-AMINOBUTYRIC ACID; HYPERALGESIA; MALE; MEXILETINE; MICE; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; THIOPHENES; TISSUE DISTRIBUTION;

EID: 84862491803     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187401     Document Type: Article

References (38)

1. Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Tsuneoka N, and Kanematsu T (2008) Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. Carcinogenesis 29:830-833. (Pubitemid 351494172)
2. Alessandri-Haber N, Dina OA, Yeh JJ, Parada CA, Reichling DB, and Levine JD (2004) Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 24:4444-4452. (Pubitemid 38608155)
3. Authier N, Gillet JP, Fialip J, Eschalier A, and Coudore F (2000) Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 887:239-249. (Pubitemid 32008045)
4. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A, Sekhon SS, Leoni L, and Monga SP (2007) R-Etodolac decreases β-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 46:849-857. (Pubitemid 46529036)
5. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, and Ben-Eliyahu S (2008) Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15:2042-2052.
6. Cata JP, Weng HR, Lee BN, Reuben JM, and Dougherty PM (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72:151-169.
7. de Souza Thiago L, da Costa ES, Lopes DV, and Borojevic R (2009) Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells. Biomed Pharmacother 63:548-551.
8. Durrenberger PF, Facer P, Gray RA, Chessell IP, Naylor A, Bountra C, Banati RB, Birch R, and Anand P (2004) Cyclooxygenase-2 (Cox-2) in injured human nerve and a rat model of nerve injury. J Peripher Nerv Syst 9:15-25. (Pubitemid 38338437)
9. 2δ-1 subunit. Biol Pharm Bull 32:732-734.
10. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, and Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15-49. (Pubitemid 43214485)
11. Honda K, Nakamura A, Morino A, and Nomura A (1991) Studies on the metabolic fate of etodolac (1) absorption, distribution and excretion in mice, rats, and dogs after single administration. Iyakuhin Kenkyu 22:109-123.
12. Inoue K, Fujisawa H, Sasaki Y, Nishimura T, Nishimura I, Inoue Y, Yokota M, Masuda T, Ueda F, and Shibata Y (1991) Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac. Arzneimittelforschung 41:228-235.
13. Inoue N, Ito S, Tajima K, Nogawa M, Takahashi Y, Sasagawa T, Nakamura A, and Kyoi T (2009) Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain. J Pharmacol Sci 109:600-605.
14. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, et al. (2007) Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67:10181-10189. (Pubitemid 350070790)
15. Kaley TJ and Deangelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145:3-14.
16. Kamei J, Nozaki C, and Saitoh A (2006) Effect of mexiletine on vincristine-induced painful neuropathy in mice. Eur J Pharmacol 536:123-127.
17. Kapadia GJ, Azuine MA, Shigeta Y, Suzuki N, and Tokuda H (2010) Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis. Bioorg Med Chem Lett 20:2546-2548.
18. Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, Sasamata M, Harada S, Akama H, Tazaki H, et al. (2006) Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J Bone Miner Res 21:219-227. (Pubitemid 43265287)
19. Khwaja FS, Wynne S, Posey I, and Djakiew D (2009) 3,3′- Diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev Res 2:566-571.
20. Kohler DR and Goldspiel BR (1994) Evaluation of new drugs: paclitaxel (Taxol). Pharmacotherapy 14:3-34.
21. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB, Leoni LM, Carson DA, and Zhang XK (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 102:2525-2530. (Pubitemid 40279410)
22. Ma W and Eisenach JC (2002) Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 15:1037-1047. (Pubitemid 35469165)
23. Ma W and Eisenach JC (2003) Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 121:691-704. (Pubitemid 38367508)
24. Matsumoto M, Inoue M, Hald A, Xie W, and Ueda H (2006) Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther 318:735-740. (Pubitemid 44061248)
25. Mishima K, Nariai Y, and Yoshimura Y (2005) Etodolac, a selective cyclooxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression. Oral Oncol 41:77-81. (Pubitemid 39647123)
26. Miyano K, Tang HB, Nakamura Y, Morioka N, Inoue A, and Nakata Y (2009) Paclitaxel and vinorelbine, evoked the release of substance P from cultured rat dorsal root ganglion cells through different PKC isoform-sensitive ion channels. Neuropharmacology 57:25-32.
27. Nishida K, Kuchiiwa S, Oiso S, Futagawa T, Masuda S, Takeda Y, and Yamada K (2008) Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Sci 99:1618-1625.
28. Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, Fujisawa M, and Kawabata M (2008) Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 71:156-160. (Pubitemid 351173283)
29. Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, et al. (2005) Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41:1460-1466. (Pubitemid 40826471)
30. Polomano RC, Mannes AJ, Clark US, and Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94:293-304. (Pubitemid 33145399)
31. Rowinsky EK, Chaudhry V, Cornblath DR, and Donehower RC (1993) Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107-115.
32. Schäfers M, Marziniak M, Sorkin LS, Yaksh TL, and Sommer C (2004) Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 185:160-168. (Pubitemid 38010287)
33. Tachimori A, Yamada N, Amano R, Ohira M, and Hirakawa K (2008) Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 28:629-638. (Pubitemid 351578902)
34. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, et al. (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192-1197. (Pubitemid 32708669)
35. Xiao W, Boroujerdi A, Bennett GJ, and Luo ZD (2007) Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 144:714-720. (Pubitemid 44856756)
36. Xiao W, Naso L, and Bennett GJ (2008) Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med 9:505-517.
37. Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Maekita T, Inoue I, Ueda K, Utsunomiya H, et al. (2010) Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 126:1467-1473.
38. Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, et al. (2005) SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106:706-712. (Pubitemid 40981269)